279 related articles for article (PubMed ID: 22394358)
1. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication.
Ghosh S; O'Hare F; Lamoureux E; Vajpayee RB; Crowston JG
Clin Exp Ophthalmol; 2012; 40(7):675-81. PubMed ID: 22394358
[TBL] [Abstract][Full Text] [Related]
2. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
3. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
4. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
6. Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications.
Uzunosmanoglu E; Mocan MC; Kocabeyoglu S; Karakaya J; Irkec M
Cornea; 2016 Aug; 35(8):1112-6. PubMed ID: 27055218
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
8. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface disease in patients with ocular hypertension and glaucoma.
Stewart WC; Stewart JA; Nelson LA
Curr Eye Res; 2011 May; 36(5):391-8. PubMed ID: 21501071
[TBL] [Abstract][Full Text] [Related]
10. The influence of glaucoma medications on ocular surface disease in primary open-angle glaucoma patients with and without conjunctivochalasis.
Kocabeyoglu S; Mocan MC; Irkec M
Acta Ophthalmol; 2014 Nov; 92(7):e592-3. PubMed ID: 24774884
[No Abstract] [Full Text] [Related]
11. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
13. [Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy].
Gomes B; Turiel PR; Marques FP; Bernardo FP; Safady MV; Portes AL; Santhiago MR
Arq Bras Oftalmol; 2013 Oct; 76(5):282-7. PubMed ID: 24232941
[TBL] [Abstract][Full Text] [Related]
14. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
15. The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction.
Mocan MC; Uzunosmanoglu E; Kocabeyoglu S; Karakaya J; Irkec M
J Glaucoma; 2016 Sep; 25(9):770-4. PubMed ID: 27513901
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ocular surface disease in patients with glaucoma.
Mathews PM; Ramulu PY; Friedman DS; Utine CA; Akpek EK
Ophthalmology; 2013 Nov; 120(11):2241-8. PubMed ID: 23714318
[TBL] [Abstract][Full Text] [Related]
17. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications.
Saini M; Dhiman R; Dada T; Tandon R; Vanathi M
Eye (Lond); 2015 Jun; 29(6):808-14. PubMed ID: 25857609
[TBL] [Abstract][Full Text] [Related]
18. Ocular symptoms and signs with preserved and preservative-free glaucoma medications.
Jaenen N; Baudouin C; Pouliquen P; Manni G; Figueiredo A; Zeyen T
Eur J Ophthalmol; 2007; 17(3):341-9. PubMed ID: 17534814
[TBL] [Abstract][Full Text] [Related]
19. Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort.
Halkiadakis I; Kontadakis GA; Tsiakou D; Patsea E; Mitropoulos P; Kandarakis AS
J Ocul Pharmacol Ther; 2015; 31(6):330-4. PubMed ID: 26133056
[TBL] [Abstract][Full Text] [Related]
20. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
